YAP1 and sarcoma: Consistent with this finding, suppression of nuclear YAP1/TAZ-TEAD transcriptional activity employing the small molecule inhibitor verteporfin resulted in a significant reduction of sarcoma cell growth and viability in vitro and in vivo, indicating requirement for YAP1/TAZ activity and the potential of YAP1/TAZ-TEAD inhibition as a novel therapeutic approach in sarcoma patients with nuclear YAP1/TAZ activity.